Research programme: anticancer therapeutics - Jerini/Merck
Alternative Names: PIN 1 inhibitors - Jerini/MerckLatest Information Update: 04 Dec 2007
At a glance
- Originator Jerini
- Developer Jerini; Merck KGaA
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 04 Jul 2006 No development reported - Preclinical for Cancer in Germany (unspecified route)
- 04 Feb 2004 Preclinical trials in Cancer in Germany (unspecified route)